Tesamorelin
Targeted visceral fat reduction
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue specifically studied for its ability to reduce visceral adipose tissue — the dangerous fat surrounding internal organs. It is the only peptide FDA-approved (as Egrifta) for lipodystrophy-related visceral fat.
Research Benefits
How It Works
Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating growth hormone release which then promotes lipolysis — specifically in visceral adipose depots. It increases IGF-1 levels and shifts the body toward fat oxidation.
Quick Reference — Tesamorelin
10 mg vial
2 mL bacteriostatic water
5 mg/mL
1–2 mg (0.2–0.4 mL)
Once daily, fasted (evening preferred)
SC injection
Refrigerate; use within 30 days
Requires bacteriostatic water for reconstitution — available in our store. Unlike CJC, designed for once-daily use. Specifically effective for visceral fat. Fasted state critical. 3–6 month cycles typical. May require break to prevent receptor downregulation.
For research purposes only. Not for human consumption. Always consult qualified professionals.
Pairs well with
Tesamorelin + CJC+IPA creates a comprehensive GH optimisation protocol. Adding Retatrutide amplifies metabolic fat burning, while MOTS-C provides mitochondrial-level metabolic support.
Questions about Tesamorelin?
Our team responds within 24 hours. Reach out for bulk pricing, stacking advice, or technical questions.